One-year follow-up of young people with ME/CFS following infectious mononucleosis by Epstein-Barr virus.
Pricoco, Rafael, Meidel, Paulina, Hofberger, Tim et al. · Frontiers in pediatrics · 2023 · DOI
Quick Summary
This study followed 25 young people (12 teenagers and 13 young adults) who developed ME/CFS after having infectious mononucleosis caused by Epstein-Barr virus. Researchers checked on their symptoms and quality of life at the start, 6 months, and 12 months later. Teenagers showed better improvement over the year, with more than half no longer meeting ME/CFS criteria, while young adults continued to have severe symptoms with little improvement.
Why It Matters
This study provides rare longitudinal evidence that ME/CFS triggered by EBV has significantly different outcomes depending on age at onset, suggesting adolescents may have better recovery potential than adults. The finding of a median 13.8-month diagnostic delay highlights critical gaps in medical recognition and supports the urgent need for better diagnostic tools and targeted treatments.
Observed Findings
54% of adolescents (6/12) no longer met ME/CFS diagnostic criteria after one year, compared to 0% of young adults (0/13).
Median time from symptom onset to ME/CFS diagnosis was 13.8 months (range: 9.1-34.9), indicating substantial diagnostic delay.
Young adults showed progressive worsening in fatigue severity, physical functioning, mental functioning, and health-related quality of life throughout the study year.
EBV serology levels and EBV DNA load did not correlate with distinct clinical features of ME/CFS.
Standard clinical chemistry showed no evidence of active inflammation in either age group.
Inferred Conclusions
Age at ME/CFS onset is a significant prognostic factor, with adolescents having substantially better recovery prospects than young adults.
Current diagnostic and laboratory approaches are insufficient for early case identification and cannot distinguish ME/CFS severity or trajectory using standard biomarkers.
Conventional medical care provides limited therapeutic benefit, particularly for adult patients, necessitating development of targeted interventions.
Remaining Questions
What biological or physiological mechanisms explain the marked difference in prognosis between adolescents and young adults?
What This Study Does Not Prove
This study does not establish that EBV causes ME/CFS in all cases, only that it can trigger the condition in some young people. The lack of inflammatory markers and EBV correlation does not prove absence of biological dysfunction—it may reflect current limitations in detecting relevant pathophysiology. The small sample size and single-center design limit generalizability to broader populations.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.